Choreo LLC Makes New Investment in Medpace Holdings, Inc. $MEDP

Choreo LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,441 shares of the company’s stock, valued at approximately $452,000.

Other institutional investors have also made changes to their positions in the company. Mawer Investment Management Ltd. lifted its holdings in Medpace by 17.4% during the 2nd quarter. Mawer Investment Management Ltd. now owns 817,432 shares of the company’s stock valued at $256,559,000 after purchasing an additional 121,213 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Medpace by 79.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 265,270 shares of the company’s stock worth $83,258,000 after buying an additional 117,301 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its stake in shares of Medpace by 675.8% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 121,464 shares of the company’s stock worth $37,009,000 after buying an additional 105,807 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Medpace by 9.4% during the 1st quarter. Invesco Ltd. now owns 1,186,768 shares of the company’s stock worth $361,596,000 after buying an additional 102,015 shares during the period. Finally, Northern Trust Corp grew its stake in Medpace by 36.0% in the 1st quarter. Northern Trust Corp now owns 337,489 shares of the company’s stock valued at $102,830,000 after buying an additional 89,347 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MEDP shares. BMO Capital Markets started coverage on Medpace in a report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective for the company. TD Cowen boosted their price target on Medpace from $356.00 to $462.00 and gave the company a “sell” rating in a research note on Friday, October 24th. Barclays upped their price objective on Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a report on Friday, October 24th. Wall Street Zen raised Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Finally, Rothschild Redb cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, ten have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and an average target price of $487.18.

Medpace Stock Down 1.2%

MEDP stock opened at $576.49 on Thursday. The company’s 50-day moving average price is $565.74 and its two-hundred day moving average price is $450.35. The firm has a market cap of $16.24 billion, a P/E ratio of 40.31, a P/E/G ratio of 2.21 and a beta of 1.43. Medpace Holdings, Inc. has a 12 month low of $250.05 and a 12 month high of $626.26.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The firm’s quarterly revenue was up 23.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Buying and Selling at Medpace

In related news, CEO August J. Troendle sold 23,178 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $593.25, for a total value of $13,750,348.50. Following the sale, the chief executive officer directly owned 652,550 shares of the company’s stock, valued at $387,125,287.50. This trade represents a 3.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Kevin M. Brady sold 3,000 shares of Medpace stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the completion of the transaction, the chief financial officer owned 6,000 shares in the company, valued at approximately $3,542,100. This represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 387,257 shares of company stock valued at $232,992,066. 20.30% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.